Psychedelic Medicine
July 22, 2026
Idir Zaher, Jérémie K. Richard
Introduction: The renewed clinical interest in psychedelics is often framed in ways that blur the distinction between psychotherapy and the psychedelic drug experience itself. Revisiting early research and clinical observations from the first wave of psychedelic science may help clarify how these processes were originally conceptualized. In the mid-20th century, LSD and other serotonergic...
International Journal of Eating Disorders
July 2, 2026
Elena Koning, Jérémie Richard, Aaron Keshen
OBJECTIVE: Eating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the...
June 12, 2026
Zane Qarni, Jérémie Richard
preprint
Interest in psychedelics has expanded beyond clinical treatment contexts, yet little empirical work has examined how users describe psychedelic use in relation to sport and physical activity. This study conducted a qualitative content analysis of Reddit discussions involving psychedelics and physical performance. A Reddit search for “sports psychedelics” returned 253 threads. After screening,...
Journal of Psychoactive Drugs
November 9, 2025
James M Zech, Jérémie Richard, Grant Jones
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
Gen Psychiatr
February 19, 2025
Jérémie Richard, Albert Garcia‐romeu, Jack E Henningfield
7 citations
The United States Food and Drug Administration’s (FDA’s) August 2024 determination that an additional phase III study will be required to consider the approval of midomafetamine for the treatment of post-traumatic stress disorder (PTSD) could delay the potential approval of this promising treatment by several years.
Psychedelic Medicine
February 7, 2025
Jérémie Richard, Michael Levine
12 citations
The topic of psychological support and psychotherapy in the context of clinical investigations of psychedelic drugs is an often debated, yet predominantly unresolved issue in the field. Psychological support, as a concept, is poorly defined and there appears to be little agreement in the field regarding its essential components, boundaries and limits. While researchers have turned their...
Christopher P. Albertyn, Jérémie Richard, Ron Joseph Shore et al.
preprint
Demoralization syndrome (DS) - a distinct clinical entity characterized by helplessness, hopelessness, and a persistent loss of meaning - affects approximately one in five Canadians with advanced cancer and is associated with increased desire for hastened death, negative clinical outcomes, and higher economic burden, yet recognition and treatment of DS remains suboptimal in modern oncology....